Gujarat Themis Biosyn FY26 profit slips to ₹46.68 cr

Key takeaway from the FY26 earnings

Gujarat Themis Biosyn Limited reported a net profit of ₹46.68 crore for the year ended March 31, 2026, even as income expanded during the period. Total income for FY26 rose to ₹168.25 crore, and income from operations increased to ₹165.82 crore versus ₹150.80 crore in the previous year. The company’s FY26 profit, however, was lower than the prior year’s ₹48.77 crore. The numbers highlight a year where topline growth continued but profit was slightly softer compared to FY25.

FY26 headline numbers in rupee terms

For FY26, the company disclosed total income of ₹168.25 crore and net profit of ₹46.68 crore. Income from operations stood at ₹165.82 crore, up from ₹150.80 crore in FY25. A separate performance summary in the provided data also described FY26 revenue growth of 9.96% to ₹165.82 crore and PAT of ₹46.68 crore. Together, these figures show that the revenue line moved higher year-on-year while PAT edged down from the prior year.

Q4 FY26 performance: revenue growth and profit print

In the quarter ended March 31, 2026 (Q4 FY26), Gujarat Themis Biosyn recorded a net profit of ₹10.89 crore. Income from operations for the quarter was ₹44.23 crore, while total income was ₹45.15 crore. The company’s Q4 FY26 revenue from operations was also reported as ₹44.23 crore, up 17.22% year-on-year. EBITDA for the quarter rose 20.71% to ₹19.36 crore, with an EBITDA margin of 43.79%.

Profitability metrics: EBITDA and margin disclosed for Q4

Q4 FY26 EBITDA of ₹19.36 crore and margin of 43.79% were the key operating profitability metrics disclosed in the dataset. With PAT at ₹10.89 crore in the same quarter, the reported numbers point to strong operating profitability in Q4. The quarter’s EPS was reported at ₹1.00. These disclosures give investors a clearer view of operating performance beyond revenue and PAT.

Q3 FY26: revenue up, profit down sequentially

The dataset also highlights a revenue-profit divergence in Q3 FY25-26 (Q3 FY26). Revenue was shown at 43 (₹43 crore as presented), with 2.41% QoQ growth and 9.74% YoY growth. Gross profit was shown at 17 (₹17 crore as presented) with -3.17% QoQ change and 0.64% YoY change. Net profit was shown at 12 (₹12 crore as presented), with -12.62% QoQ change and -3.93% YoY change.

Another line item explicitly states net profit in Q3 FY26 at ₹12.46 crore, down 12.63% QoQ and down 3.93% YoY. The same dataset notes that net profit declined to ₹12.46 crore from ₹14.26 crore in Q2 FY26, alongside nearly 10% sales growth year-on-year. This combination was presented as a sign of margin pressures, with profit contracting despite revenue momentum.

Dividend reference from March 2025 quarter

For the quarter ending March 2025, the company declared a dividend of ₹0.67 per share on 20 May 2025. The data also mentions a dividend yield of 0.18% for that declared dividend. While this is not part of FY26 earnings, it provides context on shareholder payouts referenced in the same information set.

Company profile and sector context

Gujarat Themis Biosyn Ltd., incorporated in 1981, is described in the dataset as a small-cap company with a market capitalisation of ₹4,404.38 crore and operating in the pharmaceuticals sector. The same source lists key products or revenue segments as Pharmaceuticals, Raw Materials and Scrap for the year ending March 31, 2025. This framing positions the company within India’s pharma manufacturing ecosystem, where quarterly performance can move with product mix, costs, and operating efficiency.

Summary table: FY26, Q4 FY26 and Q3 FY26 snapshot

Market and investor lens: what the numbers indicate

From the figures provided, FY26 shows a revenue expansion with a modest decline in annual profit versus FY25. Q4 FY26 stands out for strong year-on-year revenue growth and an EBITDA margin of 43.79%, alongside PAT of ₹10.89 crore. In contrast, Q3 FY26 was marked by profit contraction even as revenue rose, based on the disclosed QoQ and YoY movements.

The dataset itself flags this divergence as noteworthy because sales growth did not translate into higher profits in that quarter, suggesting margin pressure. Without additional disclosures on costs, product mix, or one-offs, the data points mainly to a pattern investors typically monitor closely: the relationship between revenue growth, operating profitability, and bottom-line outcomes.

Conclusion

Gujarat Themis Biosyn closed FY26 with total income of ₹168.25 crore and PAT of ₹46.68 crore, while revenue from operations rose to ₹165.82 crore. Q4 FY26 delivered year-on-year growth in revenue and EBITDA, whereas Q3 FY26 data highlighted profit pressure despite rising sales. Investors tracking upcoming results will likely watch whether revenue growth sustains and whether quarterly profit trends stabilise relative to operating metrics already disclosed.